Securitization – Large Exposure Issues Pertaining to Liquidity Support Facilities
Information
Table of contents
Guidance to be rescinded
As a result of OSFI's policy review, this guidance was identified as outdated, redundant, or no longer fit-for-purpose. It will be rescinded and removed from the website by April 1, 2025.
1. Purpose
Companies
2. Liquidity Facilities Containing Market Disruption Clauses
For the purpose of calculating an exposure to a single counterparty under Guideline B-2, where the documentation for a liquidity facility contains a restriction that permits drawdown only in the event of a general market disruption, as defined in section 2.3 of Guideline B-5, the undrawn portion of the facility should be excluded from the calculation of the exposure to that single counterparty. For internal risk management and approval purposes, general market disruption liquidity exposure should be aggregated with all other exposures of a company to the SPE for which the liquidity facility has been granted. Where a liquidity facility contains multiple tranches, the exclusion from the calculation of the exposure to that SPE is restricted to those tranches that are available only in the event of a general market disruption.
3. Liquidity Asset Purchase Agreement (LAPAs)
For the purpose of this Advisory, LAPAs are facilities used in securitization activities referred to in Guideline B-5. When exercised, LAPAs require the company granting the facility to purchase specified assets from the SPE on a non-recourse basis (except for the normal legally actionable scenarios of fraud, misrepresentation, etc.). The exercise of the facility by the SPE is not a loan to the SPE. As such, the SPE has no liability for repayment to the company for assets purchased by the company and does not create a credit exposure to the SPE.
Recognizing that the company ultimately has an exposure to the assets purchased and not to the SPE, LAPAs should be excluded from the calculation of an exposure to the SPE under Guideline B-2. An exposure to the obligor against whom the company would have legal recourse if the LAPA were drawn should be aggregated with all other exposures to that obligor.